These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30730114)

  • 1. Effect of Ocriplasmin on objectively assessed retinal function after treatment of vitreomacular diseases.
    Schatz A; Seuthe AM; Januschowski K
    Acta Ophthalmol; 2019 Aug; 97(5):e700-e705. PubMed ID: 30730114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
    Manousaridis K; Peter-Reichart S; Mennel S
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1907-1916. PubMed ID: 28681138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IMPACT OF VITREORETINAL INTERFACE ARCHITECTURE ON SUCCESSFUL VITREOMACULAR TRACTION RESOLUTION IN EYES SCHEDULED FOR INTRAVITREAL OCRIPLASMIN THERAPY.
    Paul C; Heun C; Müller HH; Fauser S; Kaymak H; Kazerounian S; Sekundo W; Mennel S; Meyer CH; Schmitz-Valckenberg S; Koss MJ; Feltgen N; Bertelmann T
    Retina; 2017 Jul; 37(7):1252-1260. PubMed ID: 27787446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography.
    Tibbetts MD; Reichel E; Witkin AJ
    JAMA Ophthalmol; 2014 Apr; 132(4):487-90. PubMed ID: 24577286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EVALUATION OF FULL-FIELD ELECTRORETINOGRAM REDUCTIONS AFTER OCRIPLASMIN TREATMENT: Results of the OASIS Trial ERG Substudy.
    Birch DG; Benz MS; Miller DM; Antoszyk AN; Markoff J; Kozma P; Meunier E; Sergott RC;
    Retina; 2018 Feb; 38(2):364-378. PubMed ID: 28198785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Full-field electroretinogram in autism spectrum disorder.
    Constable PA; Gaigg SB; Bowler DM; Jägle H; Thompson DA
    Doc Ophthalmol; 2016 Apr; 132(2):83-99. PubMed ID: 26868825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
    Stalmans P; Benz MS; Gandorfer A; Kampik A; Girach A; Pakola S; Haller JA;
    N Engl J Med; 2012 Aug; 367(7):606-15. PubMed ID: 22894573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LONG-TERM OUTCOMES IN PATIENTS WITH VITREOMACULAR TRACTION TREATED WITH A SINGLE INTRAVITREAL INJECTION OF OCRIPLASMIN.
    Tyler L; Singer M; Bell D
    Retin Cases Brief Rep; 2017 Winter; 11(1):34-37. PubMed ID: 26849382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Initial Clinical Experiences Using Ocriplasmin for the Treatment of Vitreomacular Traction with or without a Macular Hole].
    Lenk J; Matthé E; Ventzke S; Pillunat LE; Sandner D
    Klin Monbl Augenheilkd; 2018 Jan; 235(1):73-80. PubMed ID: 28282697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional improvement assessed by multifocal electroretinogram after Ocriplasmin treatment for vitreomacular traction.
    Rossi S; Testa F; Melillo P; Orrico A; Della Corte M; Simonelli F
    BMC Ophthalmol; 2016 Jul; 16():110. PubMed ID: 27430356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.
    Gandorfer A; Benz MS; Haller JA; Stalmans P; Pakola SJ; Girach A; Kampik A; Toth CA; Jaffe GJ;
    Retina; 2015 Jun; 35(6):1151-7. PubMed ID: 25741816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
    Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
    Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
    Manousaridis K; Peter S; Mennel S
    Acta Ophthalmol; 2018 May; 96(3):e409-e411. PubMed ID: 28771974
    [No Abstract]   [Full Text] [Related]  

  • 14. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
    Maier M; Abraham S; Frank C; Feucht N; Lohmann CP
    Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LONGITUDINAL MICROPERIMETRY EVALUATION AFTER INTRAVITREAL OCRIPLASMIN INJECTION FOR VITREOMACULAR TRACTION.
    Cacciamani A; Gelso A; Simonett JM; Ripandelli G; Pileri M; Stirpe M; Scarinci F
    Retina; 2017 Oct; 37(10):1832-1838. PubMed ID: 28033236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
    Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
    Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole.
    Jackson TL; Verstraeten T; Duchateau L; Lescrauwaet B
    Acta Ophthalmol; 2017 Dec; 95(8):e740-e745. PubMed ID: 28133919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection.
    Fahim AT; Khan NW; Johnson MW
    JAMA Ophthalmol; 2014 Apr; 132(4):484-6. PubMed ID: 24577241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials.
    Varma R; Haller JA; Kaiser PK
    JAMA Ophthalmol; 2015 Sep; 133(9):997-1004. PubMed ID: 26068086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocriplasmin use in a selected case with preserved visual acuity.
    Rossi S; Orrico A; Melillo P; Testa F; Simonelli F; Della Corte M
    BMC Ophthalmol; 2015 Oct; 15():146. PubMed ID: 26511080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.